circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway

Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated that circular RNAs play a crucial role in chemoresi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yutang, Dai, Yi, Wen, Chunjie, He, Shuai, Shi, Jingjing, Zhao, Dezhang, Wu, Lanxiang, Zhou, Honghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452060/
https://www.ncbi.nlm.nih.gov/pubmed/32805491
http://dx.doi.org/10.1016/j.omtn.2020.07.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452060/
https://www.ncbi.nlm.nih.gov/pubmed/32805491
http://dx.doi.org/10.1016/j.omtn.2020.07.027

Ejemplares similares